Basal Insulin Analogs in Special Populations: A Prescriber-Level Summary

What basal insulin does

Basal insulin restrains liver glucose output and supplies background insulin between meals and overnight. In type 1 diabetes, it is one part of a complete insulin plan and cannot cover meals by itself. In type 2 diabetes, basal insulin may be added when noninsulin therapy does not achieve individualized goals or when severe hyperglycemia, catabolism, or another clinical situation calls for insulin.

The 2026 ADA pharmacologic standards describe human NPH and long-acting analogs as options for fasting glucose control. U-100 glargine reduces nocturnal and clinically significant hypoglycemia compared with NPH in trials, while U-300 glargine and degludec have lower nocturnal hypoglycemia risk than U-100 glargine in comparative studies [1].

Longer action does not eliminate hypoglycemia. A missed meal, unexpected activity, alcohol, reduced kidney clearance, medication error, or an excessive basal dose can still produce a prolonged low glucose episode.

Current U.S. basal products

Insulin detemir should not appear as a routine 2026 choice. The ADA 2026 standards specifically discuss switching when a product is removed from the market and name detemir as the example [1].

Brand, biosimilar, concentration, pen maximum, dose increment, storage duration, and pediatric indication are not interchangeable details. Verify the exact National Drug Code or device, not just “glargine.”

Starting basal insulin in type 2 diabetes

The ADA 2026 standards state that starting doses can be estimated at 0.1 to 0.2 units/kg/day based on body weight and degree of hyperglycemia, followed by individualized titration [1]. That range is a clinical starting estimate, not a self-treatment instruction.

Before initiation, document:

• diabetes type and the reason insulin is needed;
• current glucose pattern, A1C, symptoms, and recent ketosis;
• kidney and liver function;
• prior severe or nocturnal hypoglycemia;
• meal regularity, activity, alcohol, and food access;
• who can operate the pen, meter, or CGM;
• current drugs that can cause hypoglycemia; and
• a written plan for low glucose, sick days, missed doses, and follow-up.

If fasting glucose reaches target but A1C remains high, simply increasing basal insulin can create overnight hypoglycemia without fixing post-meal hyperglycemia. The ADA calls this overbasalization. Warning signals include a large bedtime-to-morning glucose drop, hypoglycemia, high variability, or a fasting value at goal with persistent postprandial elevation [1].

For type 2 diabetes needing additional injectable treatment, a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is often considered before prandial insulin when appropriate, because it can address post-meal glucose with less hypoglycemia and weight gain than adding mealtime insulin [1].

Type 1 diabetes: basal insulin must continue

People with type 1 diabetes require continuous background insulin to suppress ketone production. The dose may need adjustment during fasting, illness, procedures, or reduced intake, but completely holding basal insulin can precipitate diabetic ketoacidosis. The ADA 2026 hospital standards specifically call for policies that prevent basal insulin from being held in type 1 diabetes during care transitions [2].

A basal-only plan is also incomplete for usual outpatient type 1 diabetes management. Mealtime insulin, correction strategy, carbohydrate planning, CGM or glucose monitoring, and ketone instructions are separate components.

Switching basal insulins safely

A universal “start at the same total daily dose” rule is too broad. Conversion depends on:

• the source and destination insulin;
• once- versus twice-daily dosing;
• U-100 versus U-300 formulation;
• current glucose and recent hypoglycemia;
• pregnancy, kidney function, and frailty; and
• whether the switch follows a formulary change, shortage, dosing error, or clinical problem.

The ADA notes that many switches can begin unit for unit and then be adjusted, but an initial 10% to 20% reduction can be used for people with very tight control or high hypoglycemia risk and is typically needed when switching from NPH or U-300 glargine to another insulin [1]. The relevant product label may give more specific instructions.

After a switch, increase glucose surveillance during the period when the new formulation reaches its stable effect. Do not assume that identical unit numbers produce identical glucose profiles.

Concentrated pens and dosing-error prevention

U-300 glargine and U-200 degludec deliver more units in a smaller volume than U-100 insulin. Their pens display the number of insulin units to inject, so users do not perform a concentration conversion. Never withdraw concentrated insulin from a pen with a syringe. That can cause a severe overdose.

U-300 glargine has a longer action profile and modestly lower glucose-lowering effect per unit than U-100 glargine, so some people require a higher eventual unit dose. That does not mean a person should preemptively add a fixed percentage without glucose-guided titration.

Current Toujeo labeling states that the product is indicated for adults and pediatric patients age 6 and older with diabetes and includes device-specific maximum doses and increments [3]. Current Tresiba labeling includes adults and pediatric patients age 1 and older and distinguishes U-100 from U-200 device increments [4].

Older adults

Older adults have higher hypoglycemia risk because of kidney decline, irregular meals, cognitive impairment, visual or dexterity limitations, polypharmacy, and impaired awareness. The 2026 ADA older-adult standards recommend CGM for older adults with type 1 diabetes and for those with type 2 diabetes using insulin. They also recommend simplifying complex insulin plans when burden or harm exceeds benefit [5].

Once-daily basal insulin may be reasonable for many older adults, but noninsulin therapies are often preferred in type 2 diabetes because of lower hypoglycemia risk and other benefits. The choice should match the person’s ability and support system.

Review:

• who prepares and administers each dose;
• whether the pen’s dose window can be seen;
• ability to attach and remove needles safely;
• meal reliability and access to carbohydrates;
• falls, confusion, or morning headaches that may signal nocturnal lows;
• duplicate or obsolete insulin supplies at home; and
• whether the glycemic goal should be relaxed or the plan deintensified.

Type 1 diabetes remains different: basal insulin is still required even when goals are relaxed or intake falls [5].

Chronic kidney disease and dialysis

Kidney disease can reduce insulin clearance and gluconeogenesis, increasing hypoglycemia risk. Appetite, dialysis timing, acute illness, and changes in other glucose-lowering drugs also alter insulin needs.

Current basal-insulin labels do not provide a universal eGFR-based percentage reduction. They call for individualized dosing and closer glucose monitoring. Fixed 25% reductions below one eGFR threshold or a 50% dialysis starting rule are not safe universal instructions.

When kidney function changes:

1. review CGM or meter patterns rather than fasting values alone;
2. look for overnight and between-meal lows;
3. verify the administered product and dose;
4. reassess nutrition, dialysis-day intake, and acute illness;
5. review sulfonylureas, meglitinides, and other hypoglycemia contributors; and
6. reduce and retitrate insulin when the pattern shows excess exposure.

A sudden fall in insulin requirement can also be a sign of worsening kidney function, weight loss, adrenal disease, liver disease, or reduced intake and deserves evaluation.

Pregnancy and preconception

Insulin is the preferred medication for type 1 diabetes during pregnancy and is preferred for gestational diabetes or type 2 diabetes in pregnancy when medication is needed. Pregnancy targets are tighter than routine outpatient targets, while hypoglycemia and rapidly changing insulin requirements complicate management. The ADA 2026 pregnancy standards recommend preconception planning and specialized team-based care [6].

Product evidence has evolved. The EXPECT randomized trial compared insulin degludec with detemir, both with insulin aspart, in pregnant women with type 1 diabetes and found degludec noninferior for the prespecified A1C outcome [7]. Current degludec labeling also describes pregnancy trial data [4].

This does not create one preferred basal insulin for every pregnancy. Existing control, prior insulin response, label data, clinician experience, device access, and the risks of switching during pregnancy all matter. Preconception review is safer than an unplanned formulary switch after pregnancy begins.

Children and adolescents

Pediatric labeling differs by product and has changed over time. Current U.S. labels state:

• Lantus has established pediatric use in children age 6 and older with type 1 diabetes [8];
• Toujeo is indicated in children age 6 and older with diabetes [3]; and
• Tresiba is indicated in children age 1 and older with diabetes [4].

Exact indications can differ across glargine reference and follow-on products. Pediatric dosing must account for age, pubertal changes, school and sports schedules, caregiver skill, meal variability, and the child’s ability to recognize lows. CGM and automated insulin delivery can materially change the safest plan.

Hypoglycemia prevention and glucagon

Hypoglycemia prevention starts before a dose is prescribed. Teach the person and household:

• how to recognize and confirm low glucose;
• how much fast carbohydrate to use and when to recheck;
• when a low requires emergency help;
• how alcohol, exercise, delayed meals, and kidney disease change risk;
• how to respond to CGM compression lows or sensor failure; and
• where glucagon is stored and how to use it.

The 2026 ADA hypoglycemia standards identify recent clinically significant hypoglycemia, impaired awareness, kidney failure, and cognitive impairment as major risk factors. They also list basal insulin therapy, advanced age, cardiovascular disease, CKD, food insecurity, and underinsurance among other risk factors [9].

Glucagon should be prescribed for people taking insulin or otherwise at high risk for severe hypoglycemia, and the people likely to help should know how to administer the available formulation. A prescription alone is not preparedness if it is expired, unaffordable, or no one knows where it is.

CGM and pattern-based adjustment

CGM can reveal overnight lows, dawn patterns, post-meal excursions, and variability that A1C or a single fasting value cannot show. In the MOBILE randomized trial, adults with type 2 diabetes using basal insulin without prandial insulin achieved better glycemic outcomes with CGM than with meter-only monitoring [10].

CGM data still require context. Confirm unexpected readings when symptoms and sensor values disagree, inspect injection sites, and ask whether the basal dose is compensating for late meals or missed mealtime treatment.

Injection-site and administration safety

Repeated injections into lipohypertrophy or localized amyloidosis can make absorption unpredictable. Rotate sites within an anatomic region and avoid abnormal tissue. Never share pens, even if the needle is changed.

Glargine and degludec products should not be mixed with other insulins unless the specific label says otherwise. Inspect the solution and use it only as directed for that product. Do not use a pen whose concentration or name does not match the prescription.

Storage and travel

In-use room-temperature duration differs by product and device. Current labeling, not a class-wide “28-day rule,” controls. For example, current labels give different in-use periods for glargine U-100, Toujeo, and Tresiba [3,4,8].

Protect insulin from freezing and excessive heat. For travel, keep it in hand luggage, carry extra supplies and the original pharmacy label, and avoid direct contact with ice packs. Time-zone changes and long travel days can require a written dose-timing plan.

Access and product substitutions

Glargine products may be reference, follow-on, or interchangeable biosimilar products. State substitution laws and payer formularies vary. A change in box color, pen design, concentration, or maximum dose can create errors even when the active molecule is related.

At every substitution:

1. remove obsolete pens from the active supply;
2. compare brand, generic name, and concentration;
3. demonstrate the new pen;
4. write the timing and unit dose in plain language; and
5. arrange early glucose review.

Cost matters because rationing insulin can cause severe hyperglycemia or ketoacidosis. A lower-cost NPH plan may be clinically workable for some people, but it has a different peak and schedule and requires education rather than silent substitution.

Bottom line

Basal insulin selection is a safety decision, not a ranking contest. U-300 glargine and degludec can reduce nocturnal hypoglycemia compared with U-100 glargine in trials, but access, device use, pediatric labeling, pregnancy evidence, kidney function, and the person’s glucose pattern determine the practical choice.

The most dangerous shortcuts are universal kidney dose cuts, automatic unit-for-unit switching, treating a fasting value by escalating basal insulin despite post-meal hyperglycemia, and holding all basal insulin in type 1 diabetes. Use current labels, current glucose data, and early follow-up after every change.